Gr-1 Ab administered after bone marrow transplantation plus thymus transplantation suppresses tumor growth by depleting granulocytic myeloid-derived suppressor cells.
It has been shown that allogeneic intra-bone marrow-bone marrow transplantation (IBM-BMT) plus thymus transplantation (TT) is effective in treating recipients with malignant tumors. Although TT increases the percentage of T cells in the early term after BMT, the myeloid-derived suppressor cells (MDSCs) are still the dominant population. We used the Gr-1 Ab to deplete the granulocytic MDSCs (G-MDSCs) in tumor-bearing mice that had received BMT+TT. Two weeks after the BMT, the mice injected with Gr-1 Ab showed smaller tumors than those in the control group. In addition, Gr-1 Ab significantly increased the percentages and numbers of CD4+ and CD8+ T cells, and decreased the percentages and numbers of MDSCs and G-MDSCs. No side effects of the Gr-1 Ab on recipient or donor thymus were observed. These findings indicate that Gr-1 Ab administered after BMT+TT may enhance the effectiveness of tumor suppression.
Department of Stem Cell Disorders, Kansai Medical University, Hirakata, Osaka, Japan; Department of Occupational and Environmental Health, School of Public Health, Guangdong Medical College, Dongguan, Guangdong, China.
Ming
M
Shi
Department of Stem Cell Disorders, Kansai Medical University, Hirakata, Osaka, Japan.
Ming
M
Li
Department of Stem Cell Disorders, Kansai Medical University, Hirakata, Osaka, Japan; JIMRO Co., Ltd., Takasaki, Gunma, Japan.
Yunze
Y
Cui
Department of Stem Cell Disorders, Kansai Medical University, Hirakata, Osaka, Japan; Division of Clinical Pathology, Toyooka Hospital, Toyooka, Hyogo, Japan.
Yasushi
Y
Adachi
Department of Stem Cell Disorders, Kansai Medical University, Hirakata, Osaka, Japan.
Susumu
S
Ikehara
D000818:Animals; D000831:Animals, Newborn; D000906:Antibodies / Q000008:administration & dosage / Q000276:immunology*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002452:Cell Count; D049109:Cell Proliferation; D006098:Granulocytes / Q000166:cytology*; D008297:Male; D051379:Mice; D022423:Myeloid Cells / Q000166:cytology* / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D011956:Receptors, Cell Surface / Q000276:immunology*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D013950:Thymus Gland / Q000637:transplantation*; D014184:Transplantation, Homologous
D000906:Antibodies; D011956:Receptors, Cell Surface; C551746:granulocyte receptor 1, mouse